What’s New
Explore latest events, medical insights and trends.
Real-Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry
Nirsevimab in Focus: Clinical Insights into RSV Protection
Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.
Beyond the Trials: Nirsevimab's Real-World Evidence in Action
Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.
Demystifying Pompe Disease: Asia Pompe Expert Forum - Chapter 1: Introduction to Pompe Disease
Updated Evidence from the EVEREST Phase 4 Trial
First, prospective, head-to-head data comparing Dupilumab and Omalizumab in CRSwNP and asthma patients.
Patient-Video
Request-form
